autologous blood and marrow transplantation - Blog Science ...

Table 1. Chemotherapy regimens.
Fields et al. 345
Chemotherapy regimen Maximum tolerated dose
ICE
Ifosfamide 20.1 g/m 2
Carboplatin 1800 g/m 2
Etoposide 3000 g/m 2
MITT
TNT
Mitoxantrone 90 mg/m 2
Thiotepa 1200 mg/m 2
Paclitaxel 360 mg/m 2
Mitoxantrone 48 mg/m 2
Thiotepa 750 mg/m 2
TIME*
Topotecan 36 mg/m 2
Ifosfamide 10 g/m 2
Etoposide 1500 mg/m 2
BuCy
CTC
Busulfan 16 mg/kg
Cyclophosphamide 120 mg/kg
Carboplatin 800 mg/m 2
Thiotepa 500 mg/m 2
Cyclophosphamide 6000 mg/m 2
*Dose escalation ongoing at the time of this publication.
stem cells (P=0.04) (Fig. 2A and B). The number of positive lymph nodes did
influence progression-free survival in patients with stage II breast cancer. The 5year
progression-free survival for patients with four to nine positive nodes was
80% compared with 51% for patients with more than nine positive nodes (P=0.04).
Of patients with stage III breast cancer, the presence of inflammatory breast cancer
was associated with significantly worse progression-free survival (Z^O.005).
Figure 3 illustrates progression-free survival for all patients with metastatic
breast cancer based on chemosensitivity at the time of transplant. Patients
transplanted in complete remission did significantly better than patients
transplanted with less than a complete response (P=0.00002). Of note, the type of
treatment necessary to achieve a complete remission (chemotherapy vs. surgery
and/or radiation) did not influence progression-free survival in this subgroup of
patients {P=0.56). As can be seen from the figures, there was a significant
difference in outcome for patients who achieved only a partial response to therapy
compared with patients who achieved less than a partial response (P=0.02)). Of